We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Plasma exchange therapy in systemic lupus erythematosus: A single-center retrospective cohort study.
- Authors
Özgüler, Yeşim; Ak, Tümay; Esatoğlu, Sinem Nihal; Elverdi, Tuğrul; Eşkazan, Ahmet Emre; Uğurlu, Serdal; Hatemi, Gülen; Seyahi, Emire; Melikoğlu, Melike; Fresko, İzzet; Ar, Muhlis Cem; Hamuryudan, Vedat
- Abstract
Objective: Few randomized controlled studies investigating the role of plasma exchange (PLEX) therapy shown no significant benefit in the management of lupus nephritis. However small case series have suggested potential efficacy in certain types of organ involvement in systemic lupus erythematosus (SLE). Methods: We conducted a retrospective review of patient records who received PLEX therapy between October 2013 and March 2022 at our apheresis unit. Patients under the age of 18 and those who underwent PLEX therapy for non-rheumatic and rheumatic diseases other than SLE were excluded from the study. We collected comprehensive data including the primary indication for PLEX therapy, procedural details, concurrent immunosuppressive medications, overall survival, outcomes of organ involvement, and any complications associated with PLEX therapy. Results: Among 58 patients with rheumatic diseases who underwent PLEX therapy we included 17 SLE patients. The main indication for PLEX was catastrophic antiphospholipid syndrome (n=5), diffuse alveolar hemorrhage (DAH) (n=5), neuropsychiatric involvement (n=4), thrombotic microangiopathy (n=2) and renal involvement (n=1). Nine patients experienced severe/opportunistic infections resulting in death only in 1 patient during PLEX. Additionally, 3 patients died due to active disease during PLEX. Among the survived patients PLEX therapy provided remission in 13 patients. Conclusion: PLEX can be regarded as a supplementary treatment along with immunosuppressives, particularly for a subset of SLE patients experiencing conditions such as DAH and neuropsychiatric involvement. Despite high frequency of severe/opportunistic infections only one patient died.
- Subjects
SYSTEMIC lupus erythematosus; PLASMA exchange (Therapeutics); NEPHRITIS; IMMUNOSUPPRESSIVE agents; ANTIPHOSPHOLIPID syndrome
- Publication
Journal of Turkish Society for Rheumatology, 2023, Vol 15, Issue 2, p89
- ISSN
2651-2653
- Publication type
Article
- DOI
10.4274/raed.galenos.2023.29591